Targeting drug-resistant Klebsiella pneumoniae infections
Official title: Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae
Funded at University of Illinois at Chicago · NIH-10974477 · Data updated 2026-11-12
This study is looking for better ways to treat tough infections caused by a type of bacteria called carbapenem-resistant Klebsiella pneumoniae, by finding the best combinations of antibiotics that work for each specific strain, so patients can have more effective treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | December 5, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $720,276 |
| NIH project number | 5R01AI173064-03 |
| Project ID | NIH-10974477 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with infections caused by carbapenem-resistant Klebsiella pneumoniae who have limited treatment options.
✕Less likely to help
Patients with infections caused by bacteria other than Klebsiella pneumoniae or those who are not infected with drug-resistant strains may not benefit from this research.
What this research studies
This research focuses on developing new treatment strategies for infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp), which are difficult to treat due to their resistance to many antibiotics. The approach involves creating tailored combinations of aminoglycosides and beta-lactam/beta-lactamase inhibitors to effectively combat these infections. By analyzing the specific resistance mechanisms of the bacteria, the research aims to identify the most effective antibiotic combinations for individual strains. This personalized treatment strategy could enhance the effectiveness of existing antibiotics and reduce the risk of treatment failure.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from severe infections caused by drug-resistant bacteria.
How similar studies have gone: Other research has shown promise in using combination therapies for antibiotic-resistant infections, indicating that this approach may be effective.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Bulman, Zackery P. — University of Illinois at Chicago
- Study coordinator: Bulman, Zackery P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.